Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Hollywood star Shia LaBeouf is spotted on the streets of Gavin and Stacey's hometown Barry
Chinese scientists precisely monitor solar radiation on Earth's surface
2023 Beijing Culture Forum to be held
Monster Georgia father is sentenced to 50 years in prison for poisoning his 18
Lynn Williams breaks NWSL goal
2023 Beijing Culture Forum to be held
Mark Pope introduced as Kentucky's men's basketball coach
Unfazed by danger and power, Guatemalan cardinal keeps up fight for migrants and the poor
Lynn Williams breaks NWSL goal
Michael Busch homers in his 4th straight game to power the Cubs past the Mariners 3
Georgia Republicans choose Amy Kremer, organizer of pro
Pic story of dancing couple in China's Xinjiang